Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial enrolled 268 people, all of whom received a drug called PF-00547659 at a dose of 75 mg. The trial was a long-term safety study, meaning its main purpose was to track and record any unwanted health events (called adverse events) that participants experienced while taking the drug. By the time the study ended, 149 participants had completed it, while 119 did not finish for various reasons. The reported data shows that out of the 268 people who started, 249 experienced at least one adverse event (an unwanted health occurrence recorded during the study). Of those, 53 had an adverse event serious enough that they stopped taking the drug because of it. Additionally, 80 participants experienced what are classified as "serious adverse events" — meaning events that were life-threatening, required hospitalisation, caused lasting disability, or had other significant consequences. For one of the secondary measures, the reported data shows that 63 participants developed antibodies against the drug itself (meaning their immune system produced a response to the drug). The study also tracked the amount of drug present in participants' blood at various points over time; the reported figures ranged from around 6,670 to roughly 12,960 nanograms per millilitre (nanograms per millilitre is simply a way of measuring how much of a substance is in the blood). These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 34427633) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 2 Crohn's Disease and Colitis Trial, Completed
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- You must be between 18 and 76 years old.
- You must have already taken part in one of two specific related studies (called A7281006 or A7281008) and completed the first 12 weeks of treatment, and shown signs that the treatment is working (as defined by those studies).
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- You may not be eligible if you finished the 12-week period of the related study but experienced serious side effects linked to the study drug, have an unstable health condition, or if the study doctor feels there is any other reason that would make it unsafe or difficult for you to participate.
- You may not be eligible if you are currently taking azathioprine, 6-mercaptopurine, or methotrexate (medicines often used to suppress the immune system) at any dose.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial was run
These are the locations recorded on the registry, and they are a historical record: this trial is not enrolling, so they are not places you can join it.
Primary endpoints
Number of Participants With On-Treatment Adverse Events (AEs), AEs Led to Withdrawal, and Serious Adverse Events (SAEs)
Other options
Data last synced from ClinicalTrials.gov: 29 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.